FDA – Page 106 – Pharma.Tips

Incomplete impact assessment during tech transfer validation – regulatory deficiency analysis and remediation roadmap

Addressing the Regulatory Deficiency of Incomplete Impact Assessments During Tech Transfer Validation In the pharmaceutical manufacturing landscape, a thorough impact assessment during tech transfer validation is critical for ensuring compliance…

PPQ acceptance criteria not met during system upgrades – regulatory deficiency analysis and remediation roadmap

Analysis and Remediation of Non-Compliant PPQ Acceptance Criteria Post-System Upgrades Pharmaceutical manufacturing organizations often undergo system upgrades to enhance operational efficiency and ensure compliance with evolving regulatory standards. However, when…

Traceability matrix gaps during requalification planning – how to rebuild the evidence package for inspectors

Addressing Gaps in Traceability Matrices During Requalification Planning: A Structured Approach In pharmaceutical manufacturing, maintaining compliance during requalification processes is critical, especially in relation to traceability matrices. Gaps in these…

Protocol deviation not investigated during system upgrades – regulatory deficiency analysis and remediation roadmap

Analysis of Protocol Deviations During System Upgrades: A Roadmap for Investigation and Remediation In pharmaceutical manufacturing, maintaining compliance with regulatory standards during system upgrades is imperative. However, instances of protocol…

Inadequate worst-case justification during requalification planning – documentation pitfalls that trigger 483 observations

Deficiencies in Worst-Case Justification During Requalification Planning: Mitigating Risks of Regulatory Observations In the pharmaceutical manufacturing environment, requalification represents a critical component in maintaining compliance with Good Manufacturing Practices (GMP).…

Inadequate worst-case justification during validation lifecycle – how to rebuild the evidence package for inspectors

Addressing Inadequate Worst-Case Justification During the Validation Lifecycle In pharmaceutical manufacturing, ensuring robust validation processes is imperative for maintaining compliance and ensuring product quality. A common issue encountered during regulatory…

Incomplete impact assessment during validation lifecycle – documentation pitfalls that trigger 483 observations

Managing Documentation Pitfalls in Validation Lifecycle Impact Assessments In the highly regulated environment of pharmaceutical manufacturing, ensuring compliance at every step is crucial. One common and significant issue that can…

Inadequate worst-case justification during requalification planning – how to prevent repeat validation failures

Addressing Inadequate Worst-Case Justification in Requalification Planning for Validation Success In the highly regulated world of pharmaceutical manufacturing, validation failures can have significant repercussions. One pertinent issue that arises during…

CSV not aligned to actual use during system upgrades – documentation pitfalls that trigger 483 observations

When CSV Fails to Align with Actual Use During System Upgrades: An Investigative Approach In the dynamic world of pharmaceutical manufacturing, the alignment of Computer System Validation (CSV) to actual…

Incomplete impact assessment during validation lifecycle – how to rebuild the evidence package for inspectors

Addressing Incomplete Impact Assessments in the Validation Lifecycle: Rebuilding Evidence for Inspections Incomplete impact assessments during the validation lifecycle can lead to significant regulatory scrutiny and potentially affect product quality.…

CSV not aligned to actual use during validation lifecycle – risk-based validation strategy aligned to FDA/EMA

Aligning CSV to Actual Use in the Validation Lifecycle: An Investigation Guide In the complex arena of pharmaceutical operations, the alignment of Computerized System Validation (CSV) with actual use during…

Incomplete impact assessment during inspection readiness – documentation pitfalls that trigger 483 observations

Assessing Documentation Pitfalls that Lead to Observations During Inspection Readiness In the complex world of pharmaceutical manufacturing, one common issue that can lead to FDA 483 observations is an incomplete…